Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients.

Gynecologic oncology - 1 Dec 2010

Barak Frida, Milgrom Roni, Laitman Yael, Gemer Ofer, Rabinovich Alex, Piura Benjamin, Anteby Eyal, Baruch Gilad Ben, Korach Jacob, Friedman Eitan

Abstract excerpt

OBJECTIVES: The genes associated with familial Endometrial Cancer (EC) are largely unknown. While EC is an integral part of Hereditary Non-Polyposis Colon Cancer, there is an ongoing debate if EC is indeed overrepresented in hereditary breast/ovarian cancer families. METHODS: Unselected Jewish wo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to DNA-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to MutS Homolog 2 Protein

Source

Identifiers

PMID: 20850175
DOI: 10.1016/j.ygyno.2010.08.027

Genes

BRCA1
MSH2
BRCA2
MSH6

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20850175-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients.PMID 20850175Read ↗

High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.Semantic proximity Read ↗

Identifying Ashkenazi Jewish <i>BRCA1/2</i> founder variants in individuals who do not self-report Jewish ancestrySemantic proximity Read ↗

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.Semantic proximity Read ↗

Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation.Semantic proximity Read ↗

Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.Semantic proximity Read ↗

Hereditary breast cancer in Jews.Semantic proximity Read ↗

Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome.Semantic proximity Read ↗

BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma.Semantic proximity Read ↗

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.Semantic proximity Read ↗

The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients.Semantic proximity Read ↗

Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.Semantic proximity Read ↗

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.